Aspen Neuroscience

The company’s lead clinical development program is an autologous neuron replacement therapy for idiopathic Parkinson’s disease.

A Report from a Workshop of the International Stem Cell Banking Initiative, Held in Collaboration of Global Alliance for Ipsc Therapies and the Harvard Stem

Aspen Neuroscience says its team combines scientific expertise and patient advocacy.

Aspen Neuroscience announced that it is using the MRI-guided ClearPoint Navigation System for all patients in its ASPIRO Phase 1/2a trial of dopaminergic neuron precursor cell transplantation for Parkinson’s disease.

Aspen Neuroscience reported continued safety and tolerability and sustained clinical benefit, including improvements in function, physician- and patient-reported outcomes, and quality of life.

Peer-reviewed findings describe reproducible manufacturing, leading-edge genomic quality controls and preclinical evidence supporting clinical development of an autologous iPSC-derived neuron replacement therapy for Parkinson’s disease, now entering Phase 3.

Aspen Neuroscience appointed Jeff Boerneke as general counsel and secretary.

Aspen Neuroscience completed Cohort Three dosing in its ASPIRO Phase 1/2a trial of ANPD001 for moderate to advanced Parkinson’s disease; its facility entered qualification for late-stage pivotal manufacturing and commercial readiness.

Aspen Neuroscience Careers

Aspen Neuroscience Board of Directors including Faheem Hasnain, Caryn Peterson, Tom Daniel, Damien McDevitt, Drew Spaventa, Peter Thompson & Doug Fisher.

Aspen Neuroscience appointed Kim Raineri as chief technology officer and a member of its executive team.

The leadership team of Aspen Neuroscience. Including Damien McDevitt, Edward Wirth, Andres Bratt-Leal, Ana Sousa, Angelyn Lowe, Thorsten Gorba, Xiaokui Zhang & Jennifer Whitaker.

SAN DIEGO, Calif., November 18, 2021 -- Aspen Neuroscience, Inc., a private biotechnology company developing the first autologous neuron replacement therapies

Aspen Neuroscience’s office is at 10835 Road to the Cure, Ste. 100, San Diego, CA 92121.

Aspen Neuroscience leverages stem cell biology and genomics to provide the world’s first autologous induced pluripotent stem cell (iPSC)-derived neuron replacement therapy for Parkinson's disease.